Items 1 to 25 of 26 total

per page
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information

A 77-01

ALK5 inhibitor
A 77-01 is a potent inhibitor of TGF-?? type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM.
A11948 SALE

AP26113 (Brigatinib)

ALK inhibitor
AP26113 is an orally-available, potent, and selective inhibitor of ALK with a potency of 0.62 nM against wild-type and activity against a wide range of mutants, including the crizotinib-resistant L1196M line. In a panel of EML4-ALK or NPM-ALK-positive cell lines, AP26113 has IC50 values of 4-31 nM. [1][2] AP26113 is effective against sensitive and resistant H3122 cells, reducing cell growth, suppressing ALK phosphorylation, and inducing apoptosis. In Ba/F3 cells expressing native or mutant EML4-ALK, AP26113 was active at IC50s of 10 and 24 nM, respectively. [3]


ALK inhibitor
ASP3026 is a novel and selective inhibitor for the ALK kinase. ASP3026 potently inhibited ALK kinase activity and was more selective than crizotinib in a Tyr-kinase panel.


ALK/IGF1R inhibitor
AZD-3463 is a ALK/IGF1R inhibitor.


ALK Inhibitor
Brigatinib is a highly potent and selective investigational ALK inhibitor with mean IC50 value ?? 100 nM in Ba/F3 cells.


ALK inhibitor
CEP-28122 is a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.


FAK/ALK inhibitor
CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
A11134 SALE


ALK Inhibitor
CH5424802 is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK.

Crizotinib hydrochloride

c-Met/NPM-ALK inhibitor
Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK.


TRK, ROS1, ALK inhibitor
Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity.
A14213 SALE


ALK4/ALK5 inhibitor
EW-7197 is a highly potent, selective, and orally bioavailable TGF-?? I receptor ALK4/ALK5 inhibitor with IC50 of 13 nM and 11 nM, respectively
A11175 SALE


IGF-1R Inhibitor

GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, respectively.

A11083 SALE


TGF-beta/Smad inhibitor
GW788388 is a potent, orally active and selective inhibitor of transforming growth factor beta receptor I (TGF-βR1) (activin receptor-like kinase 5, ALK5).


ALK inhibitor
HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.


ACK1/ALK inhibitor
KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.
A13238 SALE


ALK Inhibitor
LDK378 is a highly selective, orally bioavailable and ATP-competitive small molecule inhibitor of ALK (Anaplastic Lymphoma Kinase), a receptor tyrosine kinase considered to be an important lung cancer drug target.

LDK378 dihydrochloride

ALK inhibitor
LDK378 dihydrochloride is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.


ALK2 inhibitor
LDN-214117 is a selective and potent ALK2 inhibitor. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM.
A11205 SALE


ALK inhibitor
LDN193189 is a highly potent small molecule BMP inhibitor that inhibits BMP type I receptors ALK2 (IC50: 5 nM), ALK3 (IC50: 30 nM) and ALK6 (TGFβ1/BMP signaling) and subsequent SMAD phosphorylation.


ALK inhibitor
PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively.
A10712 SALE

PF-2341066 (Crizotinib)

ALK/ c-Met inhibitor
PF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM).


ALK5 inhibitor
R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5 nM.
A10826 SALE

SB 431542

TGF-beta/Smad inhibitor
SB 431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 .
A10827 SALE

SB 525334

ALK Inhibitor
SB525334 is a selective inhibitor of transforming growth factor-β receptor I (ALK5, TGF-βRI) (IC50 = 14.3 nM). Inhibits TGF-β1-induced smad2/3 nuclear localization and TGF-βRI-induced mRNA expression in kidney cells
A11157 SALE


ALK5 inhibitor
SB-505124 is a selective inhibitor of transforming growth factor-β type I receptor (ALK5), ALK4 and ALK7 (IC50 values are 47 and 129 nM for ALK5 and ALK4 respectively).

Items 1 to 25 of 26 total

per page
  1. 1
  2. 2

Set Descending Direction